Want to see LSTA full AI Analyst Report?
Top Page
Lisata Therapeutics
(NASDAQ:LSTA)
Select Model
Select Model
Rating:43Neutral
Price Target:
$1.50
▼(-17.58% Downside)
Action:Reiterated
Date:08/25/26
The score is primarily dragged down by weak financial performance—minimal and declining revenue alongside large losses and persistent cash burn—partly offset by a debt-free balance sheet. Technicals remain broadly weak versus longer-term averages (despite some near-term stabilization), and valuation signals provide limited support due to a negative P/E and no dividend yield data.
Positive Factors
Proprietary Oncology Platform
CEND is designed to improve delivery of anti-cancer agents into solid tumors, giving Lisata a differentiated platform that could support multiple combination therapies if clinical development validates its approach.
Negative Factors
Limited Commercial Revenue
Lisata lacks recurring product revenue from commercialized drugs, while losses remain far larger than sales. This leaves the business dependent on clinical success, partnerships or external capital rather than internally funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Oncology Platform
CEND is designed to improve delivery of anti-cancer agents into solid tumors, giving Lisata a differentiated platform that could support multiple combination therapies if clinical development validates its approach.
Read all positive factors
Lisata Therapeutics (LSTA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.87M
Dividend Yield0.03%
Average Volume (3M)392.98K
Price to Earnings (P/E)―
Beta (1Y)>-0.01
Revenue Growth-90.65%
EPS Growth26.48%
CountryUS
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding9,010,937
10 Day Avg. Volume268,777
30 Day Avg. Volume392,981
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.09
Price to Sales (P/S)95.05
P/FCF Ratio-1.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lisata Therapeutics Business Overview & Revenue Model
Company Description
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily ti...
How the Company Makes Money
Lisata Therapeutics does not have publicly disclosed recurring product revenue from commercialized drugs; as a clinical-stage biotech, its ability to generate revenue is primarily tied to external funding rather than ongoing sales. The company typ...
Lisata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.00K | 170.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 95.00K | 24.00K | 1.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -16.01M | -17.40M | -20.61M | -22.98M | -56.63M | -28.92M |
| Net Income | -14.62M | -16.59M | -19.98M | -20.84M | -54.23M | -27.47M |
Balance Sheet | ||||||
| Total Assets | 11.03M | 17.74M | 35.00M | 54.69M | 73.03M | 97.01M |
| Cash, Cash Equivalents and Short-Term Investments | 10.44M | 15.96M | 31.25M | 50.53M | 69.23M | 94.97M |
| Total Debt | 0.00 | 0.00 | 137.00K | 168.00K | 485.00K | 714.00K |
| Total Liabilities | 3.04M | 3.14M | 5.68M | 6.80M | 6.71M | 5.01M |
| Stockholders Equity | 8.24M | 14.86M | 29.57M | 48.15M | 66.58M | 92.25M |
Cash Flow | ||||||
| Free Cash Flow | -12.32M | -15.98M | -19.36M | -20.03M | -21.45M | -22.30M |
| Operating Cash Flow | -12.32M | -15.95M | -19.36M | -20.03M | -21.17M | -22.25M |
| Investing Cash Flow | 5.15M | 15.09M | 13.23M | 10.10M | 28.91M | -54.90M |
| Financing Cash Flow | 768.00K | 599.00K | -206.00K | 385.00K | -224.00K | 85.28M |
Lisata Therapeutics Technical Analysis
Neutral
1.82
Price Trends
2.03
Negative
2.67
Negative
3.13
Negative
Market Momentum
-0.02
Negative
58.27
Neutral
66.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Neutral. The current price of 1.82 is above the 20-day moving average (MA) of 1.46, below the 50-day MA of 2.03, and below the 200-day MA of 3.13, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 58.27 is Neutral, neither overbought nor oversold. The STOCH value of 66.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LSTA.
Lisata Therapeutics Risk Analysis
Lisata Therapeutics disclosed 83 risk factors in its most recent earnings report. Lisata Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lisata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $5.75M | -0.39 | -394.24% | ― | ― | 90.37% | |
48 Neutral | $60.38M | -3.24 | 288.40% | ― | ― | 86.10% | |
46 Neutral | $16.13M | -0.28 | -67.15% | ― | ― | 57.48% | |
45 Neutral | $3.15M | >-0.01 | -201.49% | ― | ― | 99.41% | |
43 Neutral | $14.87M | -1.13 | -113.79% | 0.03% | -90.65% | 26.48% |
* Healthcare Sector Average
LSTA
Lisata Therapeutics
1.86
-0.34
-15.45%
APVO
Aptevo Therapeutics
1.88
-25.66
-93.17%
CTXR
Citius Pharmaceuticals
0.60
-0.61
-50.41%
PCSA
Processa Pharmaceuticals
2.16
-2.33
-51.89%
APLM
Apollomics
24.50
18.75
326.09%
Lisata Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesLegal Proceedings
Lisata Therapeutics Announces Major Workforce Reduction and Retrenchment
Negative
Aug 4, 2026
On August 3, 2026, Lisata Therapeutics’ board approved an immediate workforce reduction of approximately 72%, a drastic cost-cutting move intended to lower operating expenses and support a search for strategic options. The company expects ab...
Business Operations and StrategyLegal ProceedingsM&A Transactions
Lisata Therapeutics Ends Kuva Merger, Starts Strategic Review
Negative
Jul 24, 2026
On July 24, 2026, Lisata Therapeutics terminated its March 6, 2026 merger agreement with Kuva Labs and Kuva Acquisition Corp. after the buyer failed to accept and pay for tendered shares when the offer expired on July 20, 2026. Kuva Labs informed ...
Business Operations and StrategyM&A Transactions
Lisata Therapeutics Extends Merger Timeline with Kuva Labs
Neutral
Jul 17, 2026
On July 16, 2026, Lisata Therapeutics, Inc. and Kuva Labs Inc., along with Kuva Acquisition Corp., amended their previously announced March 6, 2026 Agreement and Plan of Merger. The amendment extends the transaction’s contractual Outside Dat...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline
Negative
Jun 9, 2026
On June 8, 2026, Lisata Therapeutics, Kuva Labs and its subsidiary Kuva Acquisition Corp. amended their March 6, 2026 merger agreement, extending the deadline to commence the tender offer for Lisata’s outstanding common shares to June 10, 20...
M&A Transactions
Lisata Therapeutics Faces Uncertainty in Kuva Tender Offer
Negative
Jun 1, 2026
On May 29, 2026, Lisata Therapeutics, Kuva Labs and Kuva Acquisition Corp. amended their March 6, 2026 merger agreement so that the tender offer for all outstanding Lisata common shares would commence on June 1, 2026 instead of May 29, 2026, or on...
Business Operations and StrategyM&A Transactions
Lisata Therapeutics Revises Merger Terms, Adds Milestone CVRs
Neutral
May 29, 2026
On May 29, 2026, Lisata Therapeutics, Kuva Labs and its acquisition subsidiary amended their March 6, 2026 merger agreement, revising the offer for Lisata’s common stock from $5.00 in cash plus a $1.00 contingent value right to $4.00 in cash...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.